Logo

KZIA

Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited • NASDAQ
$10.55 ▲ 5.92% (+0.59)
Market Cap $17.09 M
52w High $26.30
52w Low $2.86
Dividend Yield 0%
P/E -0.85
Volume 35.82K
Outstanding Shares 1.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $22.29K ▼ $9.391M ▼ $-10.454M ▲ -46.899K% ▼ $-6.15 ▲ $-8.434M ▲
Q4-2024 $2.481M ▲ $22.06M ▲ $-17.954M ▼ -723.681% ▲ $-31.2 ▼ $-18.644M ▼
Q2-2024 $5 ▼ $8.883M ▼ $-8.824M ▼ -176.47M% ▼ $-18.4 ▼ $-7.949M ▲
Q4-2023 $1K ▲ $10.511M ▼ $-6.879M ▲ -687.897K% ▼ $-15.1 ▲ $-9.575M ▲
Q2-2023 $0 $13.636M $-13.586M 0% $-46.65 $-12.702M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $4.345M ▲ $6.061M ▼ $14.362M ▼ $-8.301M ▼
Q2-2025 $3.064M ▲ $17.912M ▼ $21.72M ▼ $-3.808M ▲
Q4-2024 $1.657M ▼ $21.585M ▼ $31.602M ▲ $-10.017M ▼
Q2-2024 $3.563M ▼ $24.383M ▼ $19.116M ▲ $5.268M ▼
Q4-2023 $5.241M $28.084M $16.034M $12.05M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-5.227M ▲ $-4.21M ▼ $0 $4.87M ▲ $0 $-4.21M ▼
Q4-2024 $-17.954M ▼ $-3.246M ▲ $0 ▼ $616.174K ▼ $0 ▼ $-3.246M ▲
Q2-2024 $-8.824M ▼ $-6.335M ▲ $5.241M ▲ $4.753M ▼ $3.563M ▲ $-6.335M ▲
Q4-2023 $-6.879M ▲ $-6.35M ▲ $-5.241M ▼ $7.121M ▲ $-3.965M ▼ $-6.35M ▲
Q2-2023 $-13.586M $-8.806M $7.361M $5.851M $4.391M $-8.806M

Five-Year Company Overview

Income Statement

Income Statement Kazia is still a pure development‑stage biotech: it has essentially no recurring product revenue and relies on outside funding rather than sales. The income statement shows a consistent pattern of operating losses driven mainly by research, clinical, and overhead costs. Losses have been fairly steady year to year rather than exploding, but they remain meaningful relative to the company’s small scale. The per‑share loss looks very large, but that is heavily distorted by repeated reverse stock splits rather than a sudden collapse in performance. Overall, the income statement reflects a typical early‑stage biotech profile: all expense, no commercial income yet, and profitability entirely dependent on successful drug approvals in the future.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small base of total assets and cash making up the majority of them. There is effectively no financial debt, which removes interest‑burden risk but also highlights that the company’s main liability is its accumulated operating losses. Over the past few years, cash and total assets have drifted down, and reported shareholders’ equity has slipped from positive to negative territory, signaling that cumulative losses now exceed the accounting value of the company. This combination—thin assets, negative equity, and no hard collateral—points to limited financial cushion and a heavy reliance on new equity, grants, or partnership funding to stay adequately capitalized.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, which is expected for a company funding clinical trials and overhead without any commercial revenue. There is no meaningful spending on physical assets, so virtually all cash burn is tied to ongoing R&D and corporate costs. The size of the operating and free cash outflows has been relatively stable, but even a steady burn rate can pose a challenge when the cash balance is modest. This means the company’s “runway” is naturally limited, and its future depends on periodic capital raises, milestone payments, or upfront licensing income to replenish cash rather than on internally generated funds.

Competitive Edge

Competitive Edge Kazia’s competitive position is built around a focused niche in difficult‑to‑treat cancers, especially brain tumors, where treatment options are scarce and medical need is high. Its lead drug candidate, paxalisib, is designed to cross the blood–brain barrier, something many competing cancer drugs struggle to do, which gives Kazia a clear technical angle in brain oncology. Regulatory designations such as orphan and fast track status, plus patent protection into the next decade, add layers of competitive protection if the drugs succeed. The company also runs a lean, partnership‑centric model that taps assets from larger pharma groups, helping it punch above its size. The flip side is that Kazia operates in an arena crowded with large, well‑funded oncology players, and it is highly concentrated in just a few pipeline programs—so any clinical setback would have an outsized impact on its competitive standing.

Innovation and R&D

Innovation and R&D Innovation is the core of Kazia’s story. Paxalisib targets a key cancer signaling pathway and is specifically optimized to reach tumors in the brain, with ongoing work in glioblastoma and other brain cancers, including pediatric and metastatic settings. EVT801 adds a second pillar by targeting tumor blood and lymphatic vessels with a more selective approach that aims to reduce side effects, and it is now moving into more advanced clinical testing. The newly in‑licensed NDL2 program, a first‑in‑class PD‑L1 degrader, pushes the company into cutting‑edge immuno‑oncology and could help overcome resistance to existing checkpoint inhibitors. Together, these programs create a differentiated pipeline focused on high‑need, high‑barrier indications. However, all of them are still in clinical or preclinical stages, so scientific promise is high but real‑world efficacy, safety, and commercial reach remain unproven and carry substantial development risk.

Summary

Financially, Kazia looks like a classic small biotech: no commercial revenue, recurring losses, a very small balance sheet, and steady cash burn, with negative equity underscoring limited financial buffer and dependence on fresh capital or partnerships. Strategically, it is trying to offset that fragility with a focused, innovative pipeline in brain and other hard‑to‑treat cancers, anchored by brain‑penetrant paxalisib, a selective anti‑angiogenic agent (EVT801), and an early next‑generation immunotherapy program (NDL2). Strong intellectual property, favorable regulatory designations, and a collaboration‑driven model help create a meaningful moat if the drugs reach market. Overall, the company’s outlook is highly sensitive to clinical trial outcomes and financing access: scientific upside could be significant, but so are the execution, regulatory, and funding risks typical of a small, development‑stage biotech.

NEWS

November 18, 2025 · 4:15 PM UTC

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Read more

October 27, 2025 · 7:15 AM UTC

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Read more

October 7, 2025 · 8:30 AM UTC

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

Read more

October 2, 2025 · 8:30 AM UTC

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Read more

October 1, 2025 · 9:21 AM UTC

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Read more